Eurofarma Named Top Pharma Employer in Latin America

Eurofarma ranked as Latin America's top pharmaceutical employer for the fifth consecutive year in Great Place To Work's 2026 Best Workplaces in Latin America list, placing eighth overall among 100 large companies surveyed across the region. The recognition reflects workforce retention strategies relevant to Mexico's pharmaceutical sector, where talent competition intensifies amid nearshoring-driven demand. 

Eurofarma ranked as the best pharmaceutical company to work for in Latin America for the fifth consecutive year, according to the Great Place To Work (GPTW) 2026 Best Workplaces in Latin America list. The Brazilian pharmaceutical company also placed eighth among all large companies surveyed across the region, ahead of pharma peers AbbVie and AstraZeneca.

The recognition, announced by Great Place To Work, evaluates the workplace experience of 4.5 million employees based on survey responses from more than 2.4 million workers across over 30 countries in Latin America, including Mexico, Central America, South America, and the Caribbean. Companies rank in one of two categories, small and medium (50-499 employees), and large (500 or more employees), and must first appear on a national Best Workplaces list to qualify for regional recognition.

“More than 90% of our products are not exclusive,” Marco Billi, Global CEO, Eurofarma, tells Great Place To Work regarding the company's approach to competing in a crowded generics and branded pharmaceutical market. “With alternatives on the market and competitors with the same technology and equipment, the competition comes down to people.” Billi adds that Eurofarma treats innovation broadly, extending beyond new molecules to how employees build relationships with physicians and pharmacies.

Eurofarma reported a voluntary turnover rate of 3% across its more than 13,000 employees, alongside internal metrics showing 93% of workers intend to stay with the company long-term, according to the same source. The company also fills 70% of leadership vacancies internally and maintains succession plans for 96% of leadership positions, figures that echo the workforce data published in its 2026 Integrated Sustainability Report.

Founded in 1972 in Brazil, Eurofarma began its international expansion in 2009 with the acquisition of its Argentine operation. The company now operates in 24 countries, covering 100% of Latin America, and maintains a presence in the United States and Africa. Its portfolio spans prescription medicine, generics, hospital and oncology products, over-the-counter medicine, personal care, and animal health, comprising more than 4,000 SKUs. In 2025, the company produced 630 million units, invested more than US$130 million in innovation projects and posted net revenue exceeding US$2.2 billion, according to the company.

Eurofarma entered Mexico in 2019 and has since expanded its local footprint through acquisitions, including the antibiotic Keflex from Eli Lilly in 2020, and partnerships such as the 2026 exclusive distribution agreement with Danone's Nutricia division for specialized nutrition products. 

Mexico's pharmaceutical sector remains the second-largest market in Latin America after Brazil and the 12th largest globally. The country's pharmaceutical and health sector accounted for approximately 5.1% of national gross domestic product in 2024, supported by a workforce pipeline of graduates in pharmaceutical chemistry, biotechnology and biomedical engineering that industry executives describe as a key competitive advantage for attracting manufacturing and research investment.

Workplace culture has become an increasingly cited differentiator for multinational pharmaceutical companies operating in Mexico, where retaining specialized talent competes with broader nearshoring-driven demand for skilled labor across manufacturing sectors. Trust-based leadership models applied through frameworks like GPTW's Trust Index have shown measurable ties to institutional resilience. The source noted that certified workplaces consistently demonstrated stronger organizational stability through periods of economic disruption, including the pandemic.

For Eurofarma, the fifth consecutive GPTW recognition follows a broader push to formalize its culture-building practices as it scales operations. The company invests annually in an in-house master's in business administration program that uses real internal business cases and is expanding to additional countries this year, according to Billi. The company also runs an intrapreneurship initiative, CLIC, that rewards employees for developing new internal processes or launching projects within the organization.

Eurofarma's 2026 Integrated Sustainability Report, audited by KPMG under Global Reporting Initiative and SASB standards, also disclosed that 89% of employees report feeling proud to work at the company and that women hold 62% of C-level positions and 66% of roles within its innovation division. Maria del Pilar Muñoz, Vice President of Sustainability and New Business, Eurofarma, says the integrated report demonstrates how sustainability considerations, including workforce development, remain central to the company's business decisions.